Orgenesis Inc. (ORGS)
- Previous Close
0.5129 - Open
0.5020 - Bid 0.4745 x 100
- Ask 0.5420 x 100
- Day's Range
0.4925 - 0.5082 - 52 Week Range
0.2500 - 1.5000 - Volume
24,462 - Avg. Volume
238,257 - Market Cap (intraday)
17.422M - Beta (5Y Monthly) 1.10
- PE Ratio (TTM)
-- - EPS (TTM)
-1.9100 - Earnings Date May 8, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.
orgenesis.comRecent News: ORGS
Performance Overview: ORGS
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ORGS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ORGS
Valuation Measures
Market Cap
17.42M
Enterprise Value
39.21M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
27.75
Price/Book (mrq)
--
Enterprise Value/Revenue
73.97
Enterprise Value/EBITDA
-0.65
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-61.86%
Return on Equity (ttm)
-339.08%
Revenue (ttm)
530k
Net Income Avi to Common (ttm)
-55.36M
Diluted EPS (ttm)
-1.9100
Balance Sheet and Cash Flow
Total Cash (mrq)
837k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
5.76M